Commenting on these results, ProMIS President and CEO, Dr. Elliot Goldstein, stated: "Our latest data lend further support to the potential best in class profile of PMN310.
We previously reported greater selectivity and binding of humanized PMN310 for toxic, amyloid beta (A beta) oligomers in direct comparison to other amyloid beta-directed antibodies, including aducanumab."
Aged mice were studied to assess and compare the ability of humanized PMN310 (huPMN310) and aducanumab to cross the blood brain barrier (BBB) and penetrate the CNS.
617 901-0785Dr. Elliot GoldsteinPresident and Chief Executive Officer, ProMIS Neurosciences Inc.Tel.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.Source: ProMIS Neurosciences via Globenewswire
May 8, 2024
Building Brain Health for Dementia Prevention